Unlocking the epigenetic code: future Frontiers in predictive biomarkers for intellectual disability in fragile X syndrome
Human Molecular Genetics · 10.08.2026 · 35 (17)
DOI: 10.1093/hmg/ddag081 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Human Molecular Genetics, online erschienen am 21.08.2026. Verfasst von Hanan Ali Alatawi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Science, University College of Haqel, University of Tabuk, Tabuk 71491, Saudi Arabia. Hauptthemen laut MEDLINE: Fragile X Syndrome, Intellectual Disability, Epigenesis, Genetic, Fragile X Messenger Ribonucleoprotein 1. Die Arbeit nennt 49 Literaturangaben. Gefördert von: King Salman Center for Disability Research.
Abstract (Originalsprache)
Fragile X Syndrome (FXS) remains the leading inherited cause of intellectual disability (ID), yet the classic CGG repeat expansion on the Fragile X Messenger Ribonucleoprotein 1 (FMR1) gene often fails to provide a precise prognostic map for cognitive outcomes. While the expansion is the primary trigger, the resulting epigenetic landscape, characterized by DNA hypermethylation and chromatin remodelling, is the true driver of gene silencing and phenotypic severity. This review critically evaluates the shift from traditional genetic screening to advanced epigenetic profiling as a robust framework for predicting ID in FXS. We synthesize emerging evidence on how quantitative epigenetic signatures can bridge the gap between genotype and the heterogeneous cognitive phenotypes observed in clinical practice. We explore the architecture of FMR1 silencing, emphasizing the role of mosaicism and epigenetic heterogeneity in shaping neurodevelopmental trajectories. A significant focus is placed on cutting-edge technologies, including single-cell epigenomics and CRISPR/dCas9-mediated epigenetic editing, which are transforming our ability to quantify ‘epigenetic load.’ Furthermore, we discuss the integration of machine learning algorithms to analyze multi-omics data, offering a pathway toward personalized prognostic scoring. We also address the clinical transition of peripheral biomarkers (e.g. blood-based methylation assays) as surrogates for central nervous system pathology. The future of FXS management lies in ‘precision prognosis.’ By decoding the epigenetic markers that precede and accompany cognitive decline, clinicians can move toward earlier diagnosis and targeted interventions. This review outlines a strategic roadmap for standardizing epigenetic assays, highlighting their potential to revolutionize the predictive landscape of neurodevelopmental disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biological Science, University College of Haqel, University of Tabuk, Tabuk 71491, Saudi Arabia.
- King Salman Center for Disability Research, Riyadh 11614, Saudi Arabia.
ORCID-Profile: Hanan Ali Alatawi
Förderung
- King Salman Center for Disability Research
Zitieren
APA
Alatawi, H. A., & Eldiasty, J. G. (2026). Unlocking the epigenetic code: future Frontiers in predictive biomarkers for intellectual disability in fragile X syndrome. Human Molecular Genetics, 35(17). https://doi.org/10.1093/hmg/ddag081
Vancouver
Alatawi HA, Eldiasty JG. Unlocking the epigenetic code: future Frontiers in predictive biomarkers for intellectual disability in fragile X syndrome. Human Molecular Genetics. 2026;35(17). doi:10.1093/hmg/ddag081
BibTeX
@article{Alatawi2026,
author = {Alatawi, Hanan Ali and Eldiasty, Jayda G},
title = {Unlocking the epigenetic code: future Frontiers in predictive biomarkers for intellectual disability in fragile X syndrome},
journal = {Human Molecular Genetics},
year = {2026},
volume = {35},
number = {17},
doi = {10.1093/hmg/ddag081}
}
EUVIMED